The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Open accessAbstract
BACKGROUND: Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Thyroid hormone lowers levels of serum low-density lipoprotein (LDL) cholesterol and has other potentially favorable actions on lipoprotein metabolism. Consequently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided. METHODS: We performed a randomized, placebo-controlled, double-blind, multicenter trial to assess the safety and efficacy of the thyromimetic compound eprotirome (KB2115) in lowering the level of serum LDL cholesterol in patients with hypercholesterolemia who were already receiving simvastatin or atorvastatin. In addition to statin treatment, patients received either eprotirome (at a dose of 25, 50, or 100 microg per day) or placebo. Secondary outcomes were changes in levels of serum apolipoprotein B, triglycerides, and Lp(a) lipoprotein. Patients were monitored for potential adverse thyromimetic effects on the heart, bone, and pituitary. RESULTS: The addition of placebo or eprotirome at a dose of 25, 50, or 100 microg daily to statin treatment for 12 weeks reduced the mean level of serum LDL cholesterol from 141 mg per deciliter (3.6 mmol per liter) to 127, 113, 99, and 94 mg per deciliter (3.3, 2.9, 2.6, and 2.4 mmol per liter), respectively, (mean reduction from baseline, 7%, 22%, 28%, and 32%). Similar reductions were seen in levels of serum apolipoprotein B, triglycerides, and Lp(a) lipoprotein. Eprotirome therapy was not associated with adverse effects on the heart or bone. No change in levels of serum thyrotropin or triiodothyronine was detected, although the thyroxine level decreased in patients receiving eprotirome. CONCLUSIONS: In this 12-week trial, the thyroid hormone analogue eprotirome was associated with decreases in levels of atherogenic lipoproteins in patients receiving treatment with statins. (ClinicalTrials.gov number, NCT00593047.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES
JONCKHEERE, A. R. (1954) · Biometrika · doi:10.1093/biomet/41.1-2.133 · Cited by 1,500
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.459 · Cited by 1,012
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M., Weissman, N. J., & Turco, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 644
Cited by
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Thyroid Hormone Regulation of Metabolism
Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Eprotirome therapy was associated with decreases in serum LDL, apolipoprotein B, triglycerides, and Lp(a) lipoprotein when added to statin therapy (668) and given as single therapy in primary hypercholesterolemia (670).”
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
“A recent prospective Phase II clinical trial of the thyroid hormone analogue eprotirome, designed to be a selective beta II receptor agonist, has been shown to lower both total cholesterol and Lp(a) without any change in thyroid hormone levels or untoward cardiovascular or bone effects (300).”
Self-citationMechanisms of thyroid hormone action
Brent, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60047 · Cited by 1,244
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
Self-citationNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“Indeed, KB-2115 has been shown to be very efficacious in treating hyperlipidemia (Ladenson et al., 2010).”
Thyroid hormones and cardiovascular disease
Jabbar, A., Pingitore, A., Pearce, S. H. S., Zaman, A., Iervasi, G., & Razvi, S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.174 · Cited by 729
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Direct effects of thyroid hormones on hepatic lipid metabolism
Sinha, R. A., Singh, B. K., & Yen, P. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.10 · Cited by 660
Lipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521
V Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose
Xavier, H. T., Izar, M. C., Faria Neto, J. R., Assad, M. H., Rocha, V. Z., Sposito, A. C., Fonseca, F. A., Santos, J. E. D., Santos, R. D., Bertolami, M. C., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s010 · Cited by 454
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 361
Deiodinases and their intricate role in thyroid hormone homeostasis
Luongo, C., Dentice, M., & Salvatore, D. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0218-2 · Cited by 332
Thyroid and Obesity: An Intriguing Relationship
Biondi, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1245 · Cited by 330
Selmer, C., Olesen, J. B., Hansen, M. L., Lindhardsen, J., Olsen, A.-M. S., Madsen, J. C., Faber, J., Hansen, P. R., Pedersen, O. D., Torp-Pedersen, C., et al. (2012) · BMJ · doi:10.1136/bmj.e7895 · Cited by 323
Arsenault, B. J., Boekholdt, S. M., Dubé, M.-P., Rhéaume, É., Wareham, N. J., Khaw, K.-T., Sandhu, M. S., & Tardif, J.-C. (2014) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000400 · Cited by 315
Hypothyroidism and obesity: An intriguing link
Sanyal, D., & Raychaudhuri, M. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.183454 · Cited by 286
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2019) · Thyroid · doi:10.1089/thy.2018.0664 · Cited by 271
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
The Effect of Thyroid Disorders on Lipid Levels and Metabolism
Duntas, L. H., & Brenta, G. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.01.012 · Cited by 258
Santini, F., Marzullo, P., Rotondi, M., Ceccarini, G., Pagano, L., Ippolito, S., Chiovato, L., & Biondi, B. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0067 · Cited by 240
Kelly, M. J., Pietranico-Cole, S., Larigan, J. D., Haynes, N.-E., Reynolds, C. H., Scott, N., Vermeulen, J., Dvorozniak, M., Conde-Knape, K., Huang, K.-S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4019299 · Cited by 231
Self-citationKlein, I., & Danzi, S. (2016) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2015.04.002 · Cited by 218
Self-citationBianco, A. C., Anderson, G., Forrest, D., Galton, V. A., Gereben, B., Kim, B. W., Kopp, P. A., Liao, X. H., Obregon, M. J., Peeters, R. P., et al. (2014) · Thyroid · doi:10.1089/thy.2013.0109 · Cited by 205
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Thyroid hormone signaling and the liver
Ritter, M. J., Amano, I., Hollenberg, A. N., et al. (2020) · Hepatology · doi:10.1002/hep.31296 · Cited by 188
“(39) TH also lowers LDL levels through reducing proprotein convertase subtilisin/kexin type 9 (PCSK9) levels, which is observed with administration of the TH analog, eprotirome, including in patients already on maximal statin therapy.(40,41) Also, subclinical hypothyroidism is associated with higher levels of PCSK9.”
BackgroundKokkorakis, M., Boutari, C., Hill, M. A., Kotsis, V., Loomba, R., Sanyal, A. J., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155835 · Cited by 155
Celi, F. S., Zemskova, M., Linderman, J. D., Smith, S., Drinkard, B., Sachdev, V., Skarulis, M. C., Kozlosky, M., Csako, G., Costello, R., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1329 · Cited by 125
The influence of thyroid function on the coagulation system and its clinical consequences
Elbers, L. P. B., Fliers, E., & Cannegieter, S. C. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13970 · Cited by 123
Lipoprotein(a): more interesting than ever after 50 years
Dubé, J. B., Boffa, M. B., Hegele, R. A., & Koschinsky, M. L. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835111d8 · Cited by 105
Jonas, W., Lietzow, J., Wohlgemuth, F., Hoefig, C. S., Wiedmer, P., Schweizer, U., Köhrle, J., & Schürmann, A. (2015) · Endocrinology · doi:10.1210/en.2014-1604 · Cited by 90
Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway
Goldberg, I. J., Huang, L.-S., Huggins, L. A., Yu, S., Nagareddy, P. R., Scanlan, T. S., & Ehrenkranz, J. R. (2012) · Endocrinology · doi:10.1210/en.2012-1572 · Cited by 80
Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator gC-1
Yuan, C., Lin, J. Z. H., Sieglaff, D. H., Ayers, S. D., DeNoto-Reynolds, F., Baxter, J. D., & Webb, P. (2012) · Endocrinology · doi:10.1210/en.2011-1325 · Cited by 70
“KB2115 also works additively with another cholesterol-lowering therapy, statins, to produce greater reductions in serum cholesterol (13).”
BackgroundSelf-citationVAN ZAANE, B., SQUIZZATO, A., DEBEIJ, J., DEKKERS, O. M., MEIJERS, J. C. M., VAN ZANTEN, A. P., BÜLLER, H. R., GERDES, V. E. A., CANNEGIETER, S. C., & BRANDJES, D. P. M. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04430.x · Cited by 46
Lombardi, A., De Matteis, R., Moreno, M., Napolitano, L., Busiello, R. A., Senese, R., de Lange, P., Lanni, A., & Goglia, F. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00037.2012 · Cited by 35
“In particular, new perspectives in this field have been opened by the introduction of potent thyromimetics with thyroid hormone receptor- isoform (TR- ) subtype-selective activities (40), and a few of them have recently entered clinical trials (25, 40).”
Backgroundvan der Valk, F., Hassing, C., Visser, M., Thakkar, P., Mohanan, A., Pathak, K., Dutt, C., Chauthaiwale, V., Ackermans, M., Nederveen, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086890 · Cited by 31
Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future
Delitala, A. P., Delitala, G., Sioni, P., & Fanciulli, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1330259 · Cited by 29
Idrees, T., Prieto, W. H., Casula, S., Ajith, A., Ettleson, M., Narchi, F. A. A., Russo, P. S. T., Fernandes, F., Johnson, J., Mayampurath, A., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab038 · Cited by 17
Bittla, P., Paidimarri, S. P., Ayuthu, S., Chauhan, Y. D., Saad, M. Z., Mirza, A. A., & Khan, S. (2024) · Cureus · doi:10.7759/cureus.69919 · Cited by 11
Novel strategies for managing dyslipidemia: treatment beyond statins
Ling, H., Burns, T. L., & Hilleman, D. E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2612 · Cited by 10
Metadata
- Authors
- Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., Olsson, A. G., Carlsson, B., Klein, I., Baxter, J. D., & Angelin, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-11
- Volume
- 362
- Issue
- 10
- Pages
- 906-916
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2097478986
- Cited by
- 338
- References
- 37
- FWCI
- 40.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.